|1.||Christenson, Robert H: 1 article (08/2005)|
|2.||Weaver, W Douglas: 1 article (08/2005)|
|3.||Turer, Aslan T: 1 article (08/2005)|
|4.||Mahaffey, Kenneth W: 1 article (08/2005)|
|5.||Every, Nathan R: 1 article (08/2005)|
|6.||Gallup, Dianne: 1 article (08/2005)|
|7.||Ohman, E Magnus: 1 article (08/2005)|
|8.||Direct Thrombin Inhibitor Trialists' Collaborative Group: 1 article (01/2002)|
|9.||PRIME Investigators: 1 article (01/2002)|
|10.||Lijnen, H R: 1 article (06/2001)|
08/23/2005 - "Both trials evaluated efegatran combined with thrombolysis for treating acute ST-segment elevation myocardial infarction (STEMI). "
01/01/2002 - "Efegatran sulfate appeared to offer no clear advantage over heparin as an adjunct to thrombolysis for acute myocardial infarction, although there may be a modest improvement in time to reperfusion."
01/01/2002 - "Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial."
08/23/2005 - "Creatine kinase (CK) and CK-MB data were analyzed, as were left ventricular ejection fraction (LVEF) by angiogram, and infarct size by single-photon emission computed tomography (SPECT) imaging in patients in 2 trials: Prompt Reperfusion In Myocardial-infarction Evolution (PRIME), and Efegatran and Streptokinase to Canalize Arteries Like Accelerated Tissue plasminogen activator (ESCALAT). "
10/01/1999 - "Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. "
08/01/1999 - "Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina."
08/01/1999 - "We investigated the safety and efficacy of five dose levels of efegatran sulphate, a direct thrombin inhibitor, compared to heparin in patients with unstable angina. "
06/01/2001 - "Efegatran was synthesized by the Hungarian Institute for Drug Research (IDR), which conducted phase II trials for angina in Hungary, and phase II trials for thrombosis in collaboration with Lilly in the US . "
04/01/1996 - "Arterial thrombus weights were reduced by GYKI-14766 [saline control = 24 +/- 4 mg, GYKI-14766 = 9 +/- 3 mg, (p < 0.05); heparin = 14 +/- 2 mg, p = NS]. "
05/01/1992 - "GYKI-14766 and heparin were found to delay thrombosis significantly when compared to vehicle-treated animals; minimum effective antithrombotic doses were 0.25 mg/kg/h and 80 U/kg + 30 U/kg/h, respectively. "
05/01/1992 - "Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis."
10/01/1996 - "In this investigation, we have studied the antithrombotic effects of combinations of minimum effective doses of the glycoprotein IIb-IIIa receptor antagonist 7E3 [murine F(ab')2] with both heparin and the novel tripeptide arginal antithrombin efegatran (LY294468) in a canine model of coronary artery thrombosis. "
|4.||Acute Coronary Syndrome
01/26/2002 - "To obtain more reliable and precise estimates of the effect of direct thrombin inhibitors in the management of acute coronary syndromes, including patients undergoing percutaneous coronary intervention, we undertook a meta-analysis based on individual patients' data from randomised trials comparing a direct thrombin inhibitor (hirudin, bivalirudin, argatroban, efegatran, or inogatran) with heparin. "
08/01/1999 - "Minor bleeding and thrombophlebitis occurred more frequently in the efegatran treated patients. "
08/01/1999 - "There were no statistically significant differences in clinical outcome or major bleeding between the efegatran and heparin groups. "
10/01/1999 - "Major bleeding occurred in 23% of patients in the efegatran/streptokinase group versus 11% in the heparin/TPA group (P = not significant). "
|4.||Tissue Plasminogen Activator (Alteplase)
|6.||Creatine Kinase (Creatine Phosphokinase)